Nevifutal is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age
Product Description : Nevifutal is a NNRTI of HIV-1. Nevirapine is a non-competitive inhibitor of the HIV-1 reverse transcriptase, but it does not have a biologically significant inhibitory effect on the HIV-2 reverse transcriptase or on eukaryotic DNA polymerases α, β, γ, or δ .
Recommended Daily Dosage :
Nevifutal should be administered by physicians who are experienced in the treatment of HIV infection
The recommended dose of Nevifutal is one 200 mg tablet daily for the first 14 days